Shin Nippon Biomedical Laboratories saw the highest growth of 0.99% in patent filings in April and 1.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of Shin Nippon Biomedical Laboratories’s patent filings and grants. Buy the databook here.
Shin Nippon Biomedical Laboratories has been focused on protecting inventions in Australia(AU) with two publications in Q2 2024
The Australia(AU) Patent Office dominates the patent grants with nearly 67% of grants. The United States(US), Australia(AU), and European Patent Office(EPO) patent Office are among the top ten patent offices where Shin Nippon Biomedical Laboratories is filings its patents. Among the top granted patent authorities, Shin Nippon Biomedical Laboratories has 67% of its grants in Australia(AU) and 33% in European Patent Office(EPO).
Bayer could be the strongest competitor for Shin Nippon Biomedical Laboratories
Patents related to rare diseases and industrial automation lead Shin Nippon Biomedical Laboratories's portfolio
Shin Nippon Biomedical Laboratories has the highest number of patents in rare diseases followed by, industrial automation. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Migraine related patents lead Shin Nippon Biomedical Laboratories portfolio followed by caries
Shin Nippon Biomedical Laboratories has highest number of patents in migraine followed by caries.
For comprehensive analysis of Shin Nippon Biomedical Laboratories's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.